REVIEW ARTICLE

Diagnosis, prognostic significance, and characteristics of new-onset right bundle-branch block in patients with acute myocardial infarction: Protocol for a systematic review and meta-analysis

Juntao Wang*, Jialu Zhu*, Hongxing Luo, Chunling Kong, Cong Zhang, Yingjie Chu

Many studies have shown that patients with AMI and bundle-branch block (BBB) may have a worse prognosis than patients with only acute myocardial infarction. Current guidelines recommend reperfusion therapy in patients with ST-segment elevation AMI or left bundle branch block AMI. Curiously, the right bundle-branch block (RBBB) is not listed as an indication for reperfusion therapy. However, some studies did not find a significant prognostic value of RBBB in acute myocardial infarction. Furthermore, distinction between old and new bundle-branch block is seldom made in previous studies. Our study is to investigate the incidence, clinical characteristics, diagnosis, and prognostic significance of new-onset RBBB in acute myocardial infarction.

METHODS AND ANALYSIS: A systematic review of studies evaluating the prognosis of right and left bundle-branch block in acute myocardial infarction will be undertaken. PubMed, EMBASE, Ovid, Cochrane Library and Web of Science will be searched electronically. Reference lists of related reviews, included studies and key journals will be manual-searched to identify further studies for inclusion. Two reviewers will independently complete publication type. Title, abstract and full-text will be screened to determine study eligibility according to the Patient-Intervention-Control-Outcomes (PICO) criteria. Data in the final included studies will be extracted. Quality assessment of included studies will be evaluated using the Newcastle-Ottawa Quality Assessment Scale. Stata 22.0 will process the data.

ETHICS AND DISSEMINATION: As data in this systematic review and meta-analysis is based on published articles, ethics approval is not required. Dissemination will be undertaken through publication in peer-reviewed journals, and the lead author’s master dissertation.

CONCLUSION: Findings may provide with valid and precise risk estimates of new-onset RBBB in AMI for clinicians and other decision-makers.

Key Words: Acute myocardial infarction; Bundle branch block; Prognosis

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com
Considering the anatomy and vascular supply of the conduction system (8,9), RBBB is usually the manifestation of large infarctions that are often accompanied by heart failure, complete AV block, arrhythmias, and a high mortality rate (10-20). The classification of RBBB according to timing, duration, and association with fascicular block is of clinical importance (17,18,21). However, studies of RBBB in AMI took place in the prethrombolytic era claimed that, thrombolytic treatment limits infarct size (22,23), improves ventricular morphology and function (24), and decreases mortality (25-28). Moreover, studies have connected the reversibility of conduction disturbances with coronary reperfusion (29,30), which suggests that reperfusion therapy can prevent the appearance or limit the duration of bundle-branch blocks. Thus, it is probable that the current wide use of reperfusion therapy may have changed the overall incidence and significance of RBBB in AMI and therefore it is reasonable to reanalyze its meaning in the reperfusion therapy era. Moreover, the American Heart Association and European Society of Cardiology in their guidelines consider AMI patients with new-onset LBBB a high-risk group and recommend for their treatment early reperfusion therapy with percutaneous coronary intervention or fibrinolytic therapy (31,32). Yet both organizations acknowledge that it is difficult to diagnose ST elevation MI in the setting of LBBB and ascertain whether the LBBB is old or new, considering that oftentimes no prior electrocardiogram is available for comparison. However, the RBBB is not listed as an indication for reperfusion therapy. Accordingly, we are conducting a systematic review and meta-analysis to assess the diagnosis, prognostic value of new RBBB in patients with AMI, in terms of risk for short- and long-time all-cause mortality, cardiac death, malignant arrhythmia, risk of heart failure, and so on.

METHODS AND ANALYSIS

This protocol was developed from the recommendations in the statement on Preferred Reporting Items for Systematic Review and Meta-Analyses Protocol (33), and is registered in PROSPERO website, (PROSPERO Registration Number: CRD42017070425). We will conduct and report this review according to the PRISMA statement (34).

Eligibility criteria

A study will be included for review if it is a full-text, original article which reports about the prognosis developed from AMI+new-RBBB, such as mortality, heart failure, complete AV block, arrhythmias and so on. We will apply the following inclusion and exclusion criteria:

**Inclusion criteria**

- Articles that report on prognosis in the population of individuals with AMI.
- Articles reporting new-RBBB and old-RBBB.
- Articles in English.

**Exclusion criteria**

- Studies are not original study.
- Studies did not report the outcomes after the AMI.
- Studies in which we are failed to obtain accurate data.
- Articles not written in English will be excluded. system cause.

**Search strategy**

On June 13, 2017, we searched the following 5 databases with similar combined items as follows:

**PubMed 373:** (Acute myocardial infarction [Title/Abstract] OR AMI [Title/Abstract] OR Acute heart infarction [Title/Abstract]) AND (("Bundle-Branch Block"[Mesh]) OR (((bundle branch block [Title/Abstract]) OR bundle-branch block [Title/Abstract]) OR BBB [Title/Abstract])) AND ("Prognosis"[Mesh]) OR ("Survival Analysis"[Mesh]) OR ("Mortality"[Mesh]) OR (prognosis [Title/Abstract]) OR survival analysis [Title/Abstract]) OR mortality [Title/Abstract]) OR death [Title/Abstract]) OR outcome [Title/Abstract]) OR Follow-up [Title/Abstract])

**Cochrane Library 66:**

#1 Acute myocardial infarction or AMI or Acute heart infarction: ti,ab,kw (Word variations have been searched) 11242
#2 MeSH descriptor: [Bundle-Branch Block] explode all trees 137
#3 bundle branch block or bundle-branch block or BBB:ti,ab,kw (Word variations have been searched) 563
#4 #2 or #3 563
#5 MeSH descriptor: [Prognosis] explode all trees 138441
#6 MeSH descriptor: [Survival Analysis] explode all trees 18933
#7 MeSH descriptor: [Mortality] explode all trees 13098
#8 prognosis or survival analysis or mortality or death or outcome or Follow-up: ti,ab,kw (Word variations have been searched) 397004
#9 #5 or #6 or #7 or #8 400951
#10 #1 and #4 and #9 66

**EMBASE 765:** 'acute heart infarction'/exp OR 'acute myocardial infarction':ab,ti OR 'ami':ab,ti OR 'acute heart infarction':ab,ti AND
Ovid (MEDLINE) 383:
1. (Acute myocardial infarction or AMI or Acute heart infarction).ab,kf,ti.
2. exp Bundle-Branch Block/
3. (bundle branch block or bundle-branch block or BBB).ab,kf,ti
4. 2 or 3
5. exp Prognosis/
6. exp Survival Analysis/
7. exp Mortality/
8. exp Follow-Up Studies/
9. (prognosis or survival analysis or mortality or death or outcome or Follow-up).ab,kf,ti.
10. 5 or 6 or 7 or 8 or 9
11. 1 and 4 and 10

Web of Science 381: TS= (Acute myocardial infarction OR AMI OR Acute heart infarction) AND TS= (bundle branch block OR bundle-branch block OR BBB) AND TS= (prognosis OR survival analysis OR mortality OR death OR outcome OR Follow-up).

Study records
Results of searched literature will be saved and the titles and abstracts of identified studies will be downloaded to NoteExpress Management software (v3.2.0.6941). Two reviewers will screen the items independently follow the eligibility criteria online (https://www.covidence.org/). After the screening of titles and abstracts, full-text will be downloaded of the remaining records. Then final set of records for inclusion will be obtained after further screening according to inclusion and exclusion criteria described in subsequent paragraphs. The reason for the exclusion will be logged in a table at the full-text stage. A third reviewer will be delegated to the discrepancies through discussion at the full-text stage. We will use a PRISMA flow diagram (35) to record the process of information acquisition during the review phases.

Data items
Data will be independently extracted by two researchers. We extracted the following items according to a uniform data extraction form:

- Author
- Year of publication
- Study design
- Study period
- Population characteristics (e.g., age, sex)
- Follow-up duration
- Sample size & new-RBBB number
- Location
- Patient involvement in outcomes selection

Outcome
Primary outcome: The incidence of cardiac death.
Secondary outcomes: major adverse cardiovascular events and all-cause mortality, malignant, risk of heart failure.

1. Arrhythmia
   - Rapid supraventricular arrhythmia (atrial flutter and atrial fibrillation, supraventricular tachycardia)
   - Bradycardia (sinoatrial/atrioventricular block above two degrees)
   - Malignant ventricular arrhythmia (ventricular tachycardia, ventricular flutter and ventricular fibrillation)
2. Heart failure
3. Cardiogenic shock
4. All-cause mortality

Risk of bias (quality) assessment
We will assess the quality of included studies using the risk of bias tool of Newcastle-Ottawa Quality Assessment. A table will be made to record the risk of bias and quality scores. Funnel plots will be made to explore the effect size of small studies, and Egger’s test will be used to test the symmetry.

Statistical analysis
Estimates for the prognosis after AMI+new-RBBB will be pooled into a meta-analysis and displayed with 95% confidence intervals.

A random effect will be used to obtain an overall summary estimate of the incidence across studies by pooling the study specific estimates.
Statistical heterogeneity across studies will be quantified by calculating I² and assessed by the Cochrane Q test. If the value of I² >50%, there is substantial heterogeneity. We will conduct a subgroup analysis to investigate the possible reasons of heterogeneity if heterogeneity is statistically significant according to the following variables: type of new-RBBB, age, country, combined disease, and so on. Furthermore, we will perform a sensitivity analysis to find out if only high-quality studies were considered how the results would change. Publication bias across studies or selective reporting bias will be assessed through the symmetry of the funnel plot. Data will be analyzed using Stata V14.0 for Windows.

**DISCUSSION**

This systematic review and meta-analysis will define the incidence data for new-RBBB in the patients after AMI. To describe the prognosis of AMI+new-RBBB, such as all-cause mortality, arrhythmia, etc. Compared with the old-RBBB, indicating the relationship between the new-RBBB and the prognosis, providing a reference for clinicians and evidence for decision maker whether to change the relevant guidelines.

Due to the language barrier, only English articles will be included in our study. This may be another limitation of this study, for which we may lose relevant data from non-English spoken areas and may cause publication bias to some extent.

**REFERENCES**


**STRENGTHS**

This systematic review will provide evidence about the incidence and prognostic significance of new-onset RBBB in patients with acute myocardial infarction.

**LIMITATIONS**

Limitations include an acknowledged language bias, as only studies published in English will be included. Furthermore, grey literature and ongoing research will also not be included in our study and this may cause publication bias to some extent.

**CONCLUSION**

A subgroup analysis, such as new-onset permanent or transient RBBB, thrombolysis or percutaneous coronary intervention, will make it possible to distinguish different prognosis in specific populations and screen the populations for optimum therapy.

**DECLARATION OF CONFLICT OF INTEREST**

None.

**TRIAL REGISTRATION NUMBER**

CRD42017070425.


